PharmaGap is pursuing pre-clinical development of its lead drug candidate, PhGα1, for use in treating cancer. PhGα1 selectively targets Protein Kinase C (PKC), a validated target for potentially treating certain types and stages of cancer. PhGα1’s compelling bioactivity, efficacy and excellent safety profile has been demonstrated in vitro and in animal models. PhGα1 has been developed by way of computer assisted rational drug design. PharmaGap’s researchers have deep knowledge of cell signaling pathways involved in the onset of cancer, particularly those controlled by the PKC family. Work is also being pursued developing a pipeline of drug modulators targeting PKC isoforms important in other disease conditions, such as heart disease and diabetes. PharmaGap’s business model strategy is to out-license its drug compounds targeting PKC prior to commencement of later-stage clinical trials in humans. Management and the board are pursuing this strategy to maximize sustainable value for shareholders. PharmaGap shares trade on Toronto’s TSX-Venture Exchange. Founded in 1999, PharmaGap is a spin-out from the National Research Council of Canada, Canada’s premier biological research organization. The Company’s development activities take place in labs and offices located in Ottawa, Ontario, Canada.
100 Sussex Drive
Ottawa, Ontario
K1A 0R6 CANADA
613.998.3400
613.998.3399 (fax)
General inquiries: info@pharmagap.com
Employment inquiries: hr@pharmagap.com
